NEWS
OKLAHOMA CITY, OKLA. – New research from the University of Oklahoma reveals a previously unknown chain of events sparking the development of cancer cachexia, a debilitating muscle-wasting condition that almost always occurs in people diagnosed with pancreatic cancer.
The research, led by Min Li, Ph.D., a professor in the OU College of Medicine, is published in the journal Cancer Cell. The study is a collaboration with researchers from Johns Hopkins School of Medicine, the University of Texas Health Science Center and Yale School of Medicine.
In the study, researchers discovered that “crosstalk” between pancreatic cancer cells and macrophages (a type of immune cell) is the first step toward the onset of cachexia. Macrophages usually protect the body from infection, but in this case, the pancreatic cancer cells recruit them to do harm. Their conversation in turn prompts increased secretion of TWEAK (TNF-like weak inducer of apoptosis), a protein known to play a role in cachexia by binding to receptors on the surface of muscle cells and causing inflammation. That sequence triggers the development of cachexia.
“Cancer cachexia is an understudied disease, and there are no good treatments, nor does nutritional support help with the symptoms,” Li said. “People lose their appetite and lose weight quickly, and because of that, they are weak and much less able to tolerate aggressive treatment for pancreatic cancer. The significance of this study is that it provides evidence of an underlying mechanism of cachexia. It is not the cancer cells alone or macrophages alone that start the process of cachexia, but the fact that they are talking to each other.”
Cancer cachexia isn’t a given with every cancer — it rarely occurs with breast cancer or brain cancer, for example — but it is most prevalent in pancreatic cancer, Li said. The study’s findings are important because by better understanding how cachexia begins, researchers can potentially develop a way to stop the cascade of events.
“It gives us a therapeutic window to intervene and potentially stop or reduce cachexia, thereby giving patients a better chance of fighting pancreatic cancer,” Li said. “Our next step is to try to develop a drug, possibly one that blocks the crosstalk between the cancer cells and the macrophages.
“This is a paradigm-shifting research publication because it represents a new way of understanding how cancer cachexia begins,” he added. “The combination of pancreatic cancer and cancer cachexia significantly diminishes a person’s quality of life. If we can determine a way to reduce the burden of cachexia, people may have a better prognosis in their fight against pancreatic cancer, which now has a five-year survival rate of only 13% and is the third-leading cause of cancer-associated deaths in the United States.”
Pancreatic cancer is notoriously difficult to find in its early stages; over 80% of patients with the disease are diagnosed when the cancer is advanced and treatment options are limited. In addition to providing a potential target for treatment, Li’s research may contribute to the ongoing search for a means of diagnosing pancreatic cancer earlier. Previous clinical studies have suggested that six to nine months before a diagnosis of pancreatic cancer, people begin losing fat then muscle.
“If a person loses more than 5% of their body weight in a six-month period for no reason, it could be a cause for concern,” he said. “Perhaps at some point, changes in a person’s body composition could help clinicians to diagnose cancer at an earlier stage before it has metastasized.”
About the project
Li holds the Virginia Kerley Cade Endowed Chair in Cancer Treatment in the OU College of Medicine and he is associate director for global oncology at OU Health Stephenson Cancer Center. This paper in Cancer Cell, “The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia,” is published online ahead of the May journal publication. It can be found at https://www.doi.org/10.1016/j.ccell.2024.03.009.
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university located in Norman, Oklahoma. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. OU was named the state’s highest-ranking university in U.S. News & World Report’s most recent Best Colleges list. For more information about the university, visit ou.edu.
Mike Banad, a researcher with the University of Oklahoma, has been awarded funding from the U.S. Department of Defense to pursue the development of advanced materials that could shape the future of energy-efficient electronics and photonics.
A new partnership between the University of Oklahoma School of Music and the Norman-based nonprofit SunHive Collective is giving OU students hands-on experience working with young adults with special needs, an opportunity that music education faculty member Melissa Baughman, Ph.D., calls “pure joy.”
The University of Oklahoma has once again been awarded the Davis Cup in recognition of its enrollment of Davis United World College Scholar freshmen. This marks the 11th time in 13 years OU has received the award. A total of 75 Davis UWC Scholars began their studies at OU this fall.
